Media stories about Kura Oncology (NASDAQ:KURA) have trended somewhat positive on Thursday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kura Oncology earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.6356526800014 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
Shares of KURA stock traded down $0.30 during trading hours on Thursday, reaching $16.90. The stock had a trading volume of 3,169 shares, compared to its average volume of 319,256. The company has a quick ratio of 12.37, a current ratio of 12.37 and a debt-to-equity ratio of 0.04. Kura Oncology has a twelve month low of $15.95 and a twelve month high of $16.30. The stock has a market cap of $538.66 million, a PE ratio of -11.12 and a beta of 4.28.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.11). equities analysts forecast that Kura Oncology will post -1.75 EPS for the current fiscal year.
KURA has been the topic of a number of recent research reports. BidaskClub upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 24th. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, March 21st. Cann restated a “buy” rating and issued a $30.00 price target on shares of Kura Oncology in a research report on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Friday, February 16th. Finally, ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Kura Oncology presently has an average rating of “Buy” and a consensus price target of $22.00.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.